By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.

Key Statistics


Email: info@iderapharma.com
Ownership: Public

Web Site: Idera Pharmaceuticals, Inc.
Employees:
Symbol: IDRA
 









Company News
Idera Pharmaceuticals, Inc. (IDRA) To Present At The 2015 Wedbush PacGrow Healthcare Conference 8/7/2015 12:30:05 PM
Idera Pharmaceuticals, Inc. (IDRA) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015 10:41:24 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Appointment Of Mark J. Casey As General Counsel And Secretary Of The Board Of Directors 6/29/2015 7:39:32 AM
Idera Pharmaceuticals, Inc. (IDRA) Enters Into A Strategic Clinical Research Alliance With M. D. Anderson Cancer Center To Advance Clinical Development Of Intratumoral TLR9 Agonist In Combination With Checkpoint Inhibitors 6/8/2015 8:01:50 AM
Idera Pharmaceuticals, Inc. (IDRA) To Present At Two June Investor Healthcare Conferences 5/27/2015 7:19:18 AM
Idera Pharmaceuticals, Inc. (IDRA) Provides Development Update On IMO-9200, An Antagonist Of Toll-Like Receptors 5/18/2015 8:51:13 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports First Quarter 2015 Financial Results And Provides Corporate Update 5/11/2015 8:33:24 AM
Idera Pharmaceuticals, Inc. (IDRA) To Present At The 14th Annual Needham Healthcare Conference 4/13/2015 8:17:19 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces FDA Orphan Drug Designation For IMO-8400 For The Treatment Of Diffuse Large B-Cell Lymphoma 4/1/2015 7:04:50 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports Fourth Quarter And Year End 2014 Financial Results And Provides Corporate Update 3/12/2015 7:48:35 AM
12345678910...
//-->